DK2139892T3 - Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer - Google Patents

Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer

Info

Publication number
DK2139892T3
DK2139892T3 DK08717594.9T DK08717594T DK2139892T3 DK 2139892 T3 DK2139892 T3 DK 2139892T3 DK 08717594 T DK08717594 T DK 08717594T DK 2139892 T3 DK2139892 T3 DK 2139892T3
Authority
DK
Denmark
Prior art keywords
pyrimidodiazepines
substituted
useful
plk1 inhibitors
plk1
Prior art date
Application number
DK08717594.9T
Other languages
Danish (da)
English (en)
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2139892(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK2139892T3 publication Critical patent/DK2139892T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK08717594.9T 2007-03-22 2008-03-11 Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer DK2139892T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (1)

Publication Number Publication Date
DK2139892T3 true DK2139892T3 (da) 2011-12-12

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08717594.9T DK2139892T3 (da) 2007-03-22 2008-03-11 Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer

Country Status (23)

Country Link
US (1) US7517873B2 (enExample)
EP (1) EP2139892B1 (enExample)
JP (1) JP5087640B2 (enExample)
KR (1) KR101157848B1 (enExample)
CN (2) CN102746175B (enExample)
AR (1) AR065794A1 (enExample)
AT (1) ATE524472T1 (enExample)
AU (1) AU2008228303B2 (enExample)
BR (1) BRPI0809088A2 (enExample)
CA (1) CA2680757A1 (enExample)
CL (1) CL2008000785A1 (enExample)
CY (1) CY1112102T1 (enExample)
DK (1) DK2139892T3 (enExample)
ES (1) ES2371832T3 (enExample)
HR (1) HRP20110807T1 (enExample)
IL (1) IL200617A (enExample)
MX (1) MX2009010034A (enExample)
PE (1) PE20120495A1 (enExample)
PL (1) PL2139892T3 (enExample)
PT (1) PT2139892E (enExample)
SI (1) SI2139892T1 (enExample)
TW (1) TWI363629B (enExample)
WO (1) WO2008113711A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190849B1 (en) * 2007-08-15 2013-11-20 Vertex Pharmceuticals Incorporated 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
NZ584760A (en) * 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
EP2610256B1 (en) * 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
EA026557B1 (ru) * 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
JP6553589B2 (ja) 2013-03-15 2019-07-31 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ピリミド−ジアゼピノン化合物および障害の治療方法
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
HRP20191525T1 (hr) 2013-11-13 2019-11-29 Vertex Pharma Inhibitori replikacije virusa influence
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
CN107074860B (zh) 2014-09-16 2022-07-15 吉利德科学公司 制备toll样受体调节剂的方法
AU2015318061B2 (en) 2014-09-16 2018-05-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256419A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
EP4034132A4 (en) * 2019-09-27 2023-10-11 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
CA3228601A1 (en) * 2021-08-10 2023-02-16 Soo Hee RYU Novel plk1 degradation inducing compound
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7491400A (en) * 1999-09-17 2001-04-17 Abbott Gmbh & Co. Kg Kinase inhibitors as therapeutic agents
NZ531928A (en) 2001-09-04 2005-10-28 Boehringer Ingelheim Pharma Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
KR20080095902A (ko) * 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
EP2139892A1 (en) 2010-01-06
JP2010521514A (ja) 2010-06-24
CL2008000785A1 (es) 2009-03-27
KR101157848B1 (ko) 2012-07-11
HK1139936A1 (en) 2010-09-30
TWI363629B (en) 2012-05-11
IL200617A (en) 2014-02-27
CN101636399B (zh) 2012-04-18
US20080234255A1 (en) 2008-09-25
PE20120495A1 (es) 2012-05-12
MX2009010034A (es) 2009-10-12
WO2008113711A1 (en) 2008-09-25
CA2680757A1 (en) 2008-09-25
SI2139892T1 (sl) 2011-12-30
AR065794A1 (es) 2009-07-01
TW200843781A (en) 2008-11-16
EP2139892B1 (en) 2011-09-14
CY1112102T1 (el) 2015-11-04
AU2008228303B2 (en) 2012-04-19
ATE524472T1 (de) 2011-09-15
JP5087640B2 (ja) 2012-12-05
BRPI0809088A2 (pt) 2014-09-09
PT2139892E (pt) 2011-11-21
CN102746175B (zh) 2014-01-15
AU2008228303A1 (en) 2008-09-25
US7517873B2 (en) 2009-04-14
KR20090119913A (ko) 2009-11-20
ES2371832T3 (es) 2012-01-10
IL200617A0 (en) 2010-05-17
CN101636399A (zh) 2010-01-27
CN102746175A (zh) 2012-10-24
PL2139892T3 (pl) 2012-03-30
HRP20110807T1 (hr) 2011-12-31

Similar Documents

Publication Publication Date Title
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
CY2017016I2 (el) Αναστολεις πρωτεασωματος
HUS1900016I1 (hu) C7-fluorral helyettesített tetraciklin vegyületek
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
DK2331547T3 (da) Pyrrolopyrimidinforbindelser som CDK-inhibitorer
DK2069324T3 (da) Fusioneret aminopyridin som hsp90-inhibitorer
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK2125748T3 (da) Acylaminopyrazol som FGFR inhibitorer
DK2102205T3 (da) Pyridopyrazinderivater anvendelige som herbicidale forbindelser
ATE502948T1 (de) Substituierte bicyclolactamverbindungen
DK2300465T3 (da) Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
BRPI0813500A2 (pt) Compostos antivirais
DK2389382T3 (da) Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer
BRPI0821086A2 (pt) Compostos inseticidas
DK2125792T3 (da) Purinderivater som immunomodulatorer
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
BRPI0908353A2 (pt) Compostos
BRPI0918602A2 (pt) composto (i)
BRPI0811264A2 (pt) Compostos
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
DK1937671T3 (da) Benzimidazolthiophenforbindelser som PLK-inhibitorer
BRPI0815181A2 (pt) Compostos